scholarly journals Neurorepair and Regeneration of the Brain: A Decade of Bioscaffolds and Engineered Microtissue

Author(s):  
Laura N. Zamproni ◽  
Mayara T. V. V. Mundim ◽  
Marimelia A. Porcionatto

Graphical AbstractBioscaffolds potential applications in tissue engineering. Bioscaffolds can be used to grow stem cells and target their differentiation in vitro(upper, left) or be used as stem cell delivery route in a brain injury (upper, right). Bioscaffolds can also contain si/miRNAs that will modify locally neural cells gene expression (lower, left) or contain exosomes/growth factors for paracrine signaling such as stimulating neurogenesis and increase neural stem migration to injury area (lower, right). This cover has been designed using resources created by Vitaly Gorbachev from Flaticon.com.

1987 ◽  
Vol 24 (5) ◽  
pp. 404-410 ◽  
Author(s):  
A. S. Waldvogel ◽  
C. A. Anderson ◽  
R. J. Higgins ◽  
B. I. Osburn

In vivo and in vitro experiments were done to investigate whether the difference in neurovirulence between the two strains of bluetongue virus 11, UC-2 and UC-8, is based on a different capability to gain access to the brain from the subcutaneous inoculation site or on a different tropism for neural cells. In newborn Balb/c mice subcutaneous inoculation of UC-8 at doses between 10−0.2 plaque forming units (PFU) and 104.8 PFU caused a severe necrotizing encephalitis whereas UC-2 at doses of up to 104.4 PFU did not affect newborn Balb/c mice. However, intracranial inoculation of 102.4 PFU of either virus strain produced severe necrotizing encephalitis. In vitro both virus strains infected dissociated brain cell cultures similarly. Double labelling immunofluorescent staining with markers specific for neural cells did not reveal differences in the target cells for the two viruses. The difference in neurovirulence between UC-2 and UC-8, therefore, appears to be determined by the ability of UC-8 to infect the brain from a subcutaneous inoculation site.


Author(s):  
Paolo Mannella ◽  
Tommaso Simoncini ◽  
Andrea Riccardo Genazzani

AbstractSex steroids are known to regulate brain function and their role is so important that several diseases are strictly correlated with the onset of menopause when estrogen-progesterone deficiency makes neural cells much more vulnerable to toxic stimuli. Although in the past years several scientists have focused their studies on in vitro and in vivo effects of sex steroids on the brain, we are still far from complete knowledge. Indeed, contrasting results from large clinical trials have made the entire issue much more complicated. Currently we know that protective effects exerted by sex steroids depend on several factors among which the dose, the health of the cells and the type of molecule being used. In this review, we present an overview of the direct and indirect effects of estrogen and progesterone on the brain with specific focus on the molecular mechanisms by which these molecules act on neural cells.


2007 ◽  
Vol 8 (3) ◽  
pp. 825-832 ◽  
Author(s):  
S. Tielens ◽  
H. Declercq ◽  
T. Gorski ◽  
E. Lippens ◽  
E. Schacht ◽  
...  

2022 ◽  
Vol 12 ◽  
Author(s):  
Mia Levite ◽  
Hadassa Goldberg

Epilepsy affects ~50 million people. In ~30% of patients the etiology is unknown, and ~30% are unresponsive to anti-epileptic drugs. Intractable epilepsy often leads to multiple seizures daily or weekly, lasting for years, and accompanied by cognitive, behavioral, and psychiatric problems. This multidisciplinary scientific (not clinical) ‘Perspective’ article discusses Autoimmune Epilepsy from immunological, neurological and basic-science angles. The article includes summaries and novel discoveries, ideas, insights and recommendations. We summarize the characteristic features of the respective antigens, and the pathological activity in vitro and in animal models of autoimmune antibodies to: Glutamate/AMPA-GluR3, Glutamate/NMDA-NR1, Glutamate/NMDA-NR2, GAD-65, GABA-R, GLY-R, VGKC, LGI1, CASPR2, and β2 GP1, found in subpopulations of epilepsy patients. Glutamate receptor antibodies: AMPA-GluR3B peptide antibodies, seem so far as the most exclusive and pathogenic autoimmune antibodies in Autoimmune Epilepsy. They kill neural cells by three mechanisms: excitotoxicity, Reactive-Oxygen-Species, and complement-fixation, and induce and/or facilitate brain damage, seizures, and behavioral impairments. In this article we raise and discuss many more topics and new insights related to Autoimmune Epilepsy. 1. Few autoimmune antibodies tilt the balance between excitatory Glutamate and inhibitory GABA, thereby promoting neuropathology and epilepsy; 2. Many autoantigens are synaptic, and have extracellular domains. These features increase the likelihood of autoimmunity against them, and the ease with which autoimmune antibodies can reach and harm these self-proteins. 3. Several autoantigens have ‘frenetic character’- undergoing dynamic changes that can increase their antigenicity; 4. The mRNAs of the autoantigens are widely expressed in multiple organs outside the brain. If translated by default to proteins, broad spectrum detrimental autoimmunity is expected; 5. The autoimmunity can precede seizures, cause them, and be detrimental whether primary or epiphenomenon; 6. Some autoimmune antibodies induce, and associate with, cognitive, behavioral and psychiatric impairments; 7. There are evidences for epitope spreading in Autoimmune Epilepsy; 8. T cells have different ‘faces’ in the brain, and in Autoimmune Epilepsy: Normal T cells are needed for the healthy brain. Normal T cells are damaged by autoimmune antibodies to Glutamate/AMPA GluR3, which they express, and maybe by additional autoantibodies to: Dopamine-R, GABA-R, Ach-R, Serotonin-R, and Adrenergic-R, present in various neurological diseases (summarized herein), since T cells express all these Neurotransmitter receptors. However, autoimmune and/or cytotoxic T cells damage the brain; 9. The HLA molecules are important for normal brain function. The HLA haplotype can confer susceptibility or protection from Autoimmune Epilepsy; 10. There are several therapeutic strategies for Autoimmune Epilepsy.


Cells ◽  
2020 ◽  
Vol 9 (11) ◽  
pp. 2434
Author(s):  
Issan Zhang ◽  
Paula Lépine ◽  
Chanshuai Han ◽  
María Lacalle-Aurioles ◽  
Carol X.-Q. Chen ◽  
...  

Inflammatory processes in the brain are orchestrated by microglia and astrocytes in response to activators such as pathogen-associated molecular patterns, danger-associated molecular patterns and some nanostructures. Microglia are the primary immune responders in the brain and initiate responses amplified by astrocytes through intercellular signaling. Intercellular communication between neural cells can be studied in cerebral organoids, co-cultures or in vivo. We used human cerebral organoids and glioblastoma co-cultures to study glia modulation by dendritic polyglycerol sulfate (dPGS). dPGS is an extensively studied nanostructure with inherent anti-inflammatory properties. Under inflammatory conditions, lipocalin-2 levels in astrocytes are markedly increased and indirectly enhanced by soluble factors released from hyperactive microglia. dPGS is an effective anti-inflammatory modulator of these markers. Our results show that dPGS can enter neural cells in cerebral organoids and glial cells in monocultures in a time-dependent manner. dPGS markedly reduces lipocalin-2 abundance in the neural cells. Glioblastoma tumoroids of astrocytic origin respond to activated microglia with enhanced invasiveness, whereas conditioned media from dPGS-treated microglia reduce tumoroid invasiveness. Considering that many nanostructures have only been tested in cancer cells and rodent models, experiments in human 3D cerebral organoids and co-cultures are complementary in vitro models to evaluate nanotherapeutics in the pre-clinical setting. Thoroughly characterized organoids and standardized procedures for their preparation are prerequisites to gain information of translational value in nanomedicine. This study provides data for a well-characterized dendrimer (dPGS) that modulates the activation state of human microglia implicated in brain tumor invasiveness.


Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Yingli Fu ◽  
Dorota Kedziorek ◽  
Veronica Crisostomo ◽  
Wesley Gilson ◽  
Nicole Azene ◽  
...  

Mesenchymal stem cell (MSC) transplantation offers an alternative strategy for therapeutic angiogenesis for the management of ischemic cardiovascular disease. However, the poor survival of transplanted cells and lack of sustained engraftment severely limits therapeutic efficacy. We propose a novel cell microencapsulation method utilizing perfluoro-octyl-bromide (PFOB) impregnated alginate-poly-L-lysine-alginate microcapsules (PFOB Caps) that enable noninvasive cell delivery and tracking using conventional clinical X-ray fluoroscopy. Microen-capsulation of rabbit MSCs (1x10 6 cells/ml) combined with PFOB-loaded alginate was performed with an electrostatic droplet generator. Control capsules lacked PFOB. MSC viability post-encapsulation was determined using a microfluorometric assay. X-ray fluoroscopy was performed during direct intramuscular/intramyocardial injection of 2300 capsules/injection in a rabbit peripheral arterial disease (PAD) model (n=2) and a swine reperfused myocardial infarction (MI) model (n=3). Fluoroscopy and angiographic computed tomography (DynaCT) were performed to assess the ability to monitor microcapsule delivery and tracking with X-ray. As compared to control capsules, PFOB Caps showed similar swelling, when subjected to 55 mM sodium citrate incubation (mean diameter increased 5.4% for PFOB vs. 4.5% for control, P=NS), and mechanical strength (broken capsules from osmotic pressure tests: 2/591 for PFOB and 2/603 for control). The PFOB Caps showed a small viability decrease immediately after encapsulation (90±3%) with no significant further viability loss up to 4 weeks in vitro (79±5%). In both PAD and MI animals, successful injection of PFOB Caps could be demonstrated with DynaCT but not with real-time fluoroscopic images. Control capsules were never detected. CT tracking of PFOB Caps was possible up to 5 weeks post-injection. PFOB microcapsules provide an ideal microenvironment for maintaining MSC viability in vitro . In addition, PFOB proves to be a non-toxic, radiopaque agent suitable for cell tracking using conventional fluoroscopy in vivo . PFOB microencapsulation of MSCs may be a novel approach for X-ray tracking therapeutic angiogenesis.


2008 ◽  
Vol 89 (12) ◽  
pp. 3177-3184 ◽  
Author(s):  
Leigh Thorne ◽  
Linda A. Terry

Scrapie is a fatal, naturally transmissible, neurodegenerative prion disease that affects sheep and goats and is characterized by the accumulation of a misfolded protein, PrPSc, converted from host-encoded PrPc, in the central nervous system of affected animals. Highly efficient in vitro conversion of host PrPc to PrPSc has been achieved in models of scrapie and in natural prion diseases by protein misfolding cyclic amplification (PMCA). Here, we demonstrate amplification, by serial PMCA, of PrPSc from individual sources of scrapie-infected sheep. Efficiency of amplification was affected by the pairing of the source of PrPSc with the control brain substrate of different genotypes of PrP. In line with previous studies, efficiency of amplification was greatly enhanced with the addition of a synthetic polyanion, polyadenylic acid (PolyA), facilitating rapid detection of low levels of PrPSc from body fluids such as blood. To this end PrPSc was amplified, in a 3 day PMCA assay, from blood leukocyte preparations from VRQ/VRQ scrapie-affected sheep at clinical end point. While PolyA-assisted PMCA resulted in spontaneous conversion of PrPc, we were able to distinguish blood samples from unaffected and affected sheep under controlled conditions. This study demonstrates that highly efficient amplification of PrPSc can be achieved for ovine scrapie from both brain and blood from naturally infected sheep and shows potential applications for improvements in current diagnostics and pre-mortem testing.


2013 ◽  
Vol 33 (suppl_1) ◽  
Author(s):  
Ali K Naji ◽  
Michael Wassler ◽  
George Britton ◽  
Harnath S Shelat ◽  
Yong-Jian Geng ◽  
...  

Introduction. We have developed bifunctional echogenic liposomes (BF-ELIP) targeted to both CD34 and ICAM-1 to facilitate delivery of CD34+ stem cells to inflammatory endothelium. We previously confirmed that BF-ELIP enhanced CD34+ stem cell adherence to ICAM-1-expressing endothelium in vitro and in vivo and showed that ultrasound (US) facilitated penetration of stem cells into the endothelial cell layer. Hypothesis. The transwell culture system can serve as an in vitro model for study of US-enhanced targeted delivery of stem cells to atheroma. Methods. BF-ELIP were prepared by evaporation-rehydration-sonication-lyophilization, followed by conjugating antibodies specific for CD34 and ICAM-1 through a thioether linkage. TNFα-pretreated HUVEC monolayers on transwell (6 wells/plate) insert membranes were incubated with nonspecific IgG-ELIP or BF-ELIP (1mg/well) for 15 minutes, followed by human monocytes labeled with Oregon Green. Half the inserts were subjected to 6 MHz color Doppler ultrasound (MI = 0.4) for 5 minutes. Fluorescence of resuspended cells was measured after treatment of both inserts and wells with 0.25% trypsin/0.1% EDTA 24 hours later. Results. BF-ELIP enhanced adherence of monocytes to the ICAM-1-expressing HUVEC monolayer relative to untreated controls and IgG-ELIP, but did not increase the number (Fig. 1) or proportion (Fig. 2) of monocytes traversing the monolayer. US greatly increased the number of monocytes both adhering to and passing through the monolayer in all groups. Conclusions. We have succeeded in developing a transwell cultured HUVEC system as a model for US-enhanced, BF-ELIP-mediated stem cell delivery to inflammatory endothelium.


Sign in / Sign up

Export Citation Format

Share Document